Abstract

Background/Objectives: Pemetrexed–platinum chemotherapy is a key treatment option for non-squamous non-small cell lung cancer (NSCLC); however, its use is often limited by hematologic toxicity, particularly neutropenia. We aimed to develop a model-informed framework for assessing neutrophil dynamics using routinely available clinical data and pemetrexed exposure. Methods: This real-world investigation included 86 patients with NSCLC who received pemetrexed–platinum chemotherapy for model development, and 83 patients who received the same chemotherapy plus pembrolizumab or bevacizumab for validation. We developed a nonlinear mixed-effects model to predict neutrophil dynamics during the first cycle following pemetrexed–platinum chemotherapy, using patient-specific clinical data collected before chemotherapy initiation and pemetrexed pharmacokinetic parameters derived from physiologically based pharmacokinetic (PBPK) modeling. Results: The final model suggested that the area under the curve (AUC)0–24 >175 μg·h/mL for pemetrexed, blood urea nitrogen, and concomitant use of renin–angiotensin system inhibitors influenced neutrophil suppression and delayed recovery. The receiver operating characteristic curve (AUROC) for identifying patients with a neutrophil count <1500/μL immediately before the anticipated next treatment cycle was 0.768 (95% CI: 0.639–0.898) in the development cohort, and 0.718 (95% CI: 0.545–0.891) in the validation cohort. Conclusions: This model-informed framework, based on PBPK-derived pemetrexed exposure and routinely available clinical factors, may help identify patients at risk of clinically relevant neutropenia that could delay the initiation of the next treatment cycle.

IPC Classification

Keywords